Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept
Aim. To study the efficacy, safety and effect on vascular age of free-equivalent and fixed-dose combinations of amlodipine, a renin-angiotensin-aldosterone system blockers and rosuvastatin in patients with high and very high cardiovascular risk with uncontrolled hypertension and concomitant dyslipid...
Saved in:
Published in | Rossiĭskiĭ kardiologicheskiĭ zhurnal Vol. 25; no. 9; p. 4026 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English Russian |
Published |
FIRMA «SILICEA» LLC
21.09.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim. To study the efficacy, safety and effect on vascular age of free-equivalent and fixed-dose combinations of amlodipine, a renin-angiotensin-aldosterone system blockers and rosuvastatin in patients with high and very high cardiovascular risk with uncontrolled hypertension and concomitant dyslipidemia.Material and methods. This open-label case series study included 148 men and women (mean age 60,63±8,16 years). The patients were randomly divided into 2 groups: group 1 (n=76) received a triple fixed-dose combination of amlodipine, lisinopril, rosuvastatin; group 2 (n=72) received a dual free-equivalent antihypertensive combination (amlodipine/losartan) and rosuvastatin. The doses were selected by the attending physician and were not regulated by the researchers. The study included an assessment of blood pressure, lipid profile (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides), biochemical profile, ASCORE value, medication adherence, changes in the augmentation index (AI) at baseline and after 6 months of therapy (first and second visits, respectively). The results were considered significant at p<0,05.Results. After 6 months of therapy, significant intragroup differences were noted in comparison with the baseline values. In group 1, the levels of TC (p=0,002), LDL-C (p=0,001), ASCORE value (p=0,01), and vascular age (p=0,01) significantly decreased; in group 2 — TC (p=0,03), LDL-C (p=0,005). In the group of triple fixed-dose therapy, the values of AI (p=0,04), TC (p=0,012), LDL-C (p=0,024), ASCORE value (p=0,02) and vascular age (p=0,01) were significantly lower than in the free-equivalent group.Conclusion. The fixed-dose combination of amlodipine, lisinopril and rosuvastatin, is more effective and equally safe relative to the free-equivalent combination of amlodipine/losartan and rosuvastatin, not only in terms of effect on LDL-C and AI, but also on vascular age parameters calculated using the ASCORE scale. This can serve as an additional motivating factor for patients to receive therapy. |
---|---|
AbstractList | Aim. To study the efficacy, safety and effect on vascular age of free-equivalent and fixed-dose combinations of amlodipine, a renin-angiotensin-aldosterone system blockers and rosuvastatin in patients with high and very high cardiovascular risk with uncontrolled hypertension and concomitant dyslipidemia.Material and methods. This open-label case series study included 148 men and women (mean age 60,63±8,16 years). The patients were randomly divided into 2 groups: group 1 (n=76) received a triple fixed-dose combination of amlodipine, lisinopril, rosuvastatin; group 2 (n=72) received a dual free-equivalent antihypertensive combination (amlodipine/losartan) and rosuvastatin. The doses were selected by the attending physician and were not regulated by the researchers. The study included an assessment of blood pressure, lipid profile (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides), biochemical profile, ASCORE value, medication adherence, changes in the augmentation index (AI) at baseline and after 6 months of therapy (first and second visits, respectively). The results were considered significant at p<0,05.Results. After 6 months of therapy, significant intragroup differences were noted in comparison with the baseline values. In group 1, the levels of TC (p=0,002), LDL-C (p=0,001), ASCORE value (p=0,01), and vascular age (p=0,01) significantly decreased; in group 2 — TC (p=0,03), LDL-C (p=0,005). In the group of triple fixed-dose therapy, the values of AI (p=0,04), TC (p=0,012), LDL-C (p=0,024), ASCORE value (p=0,02) and vascular age (p=0,01) were significantly lower than in the free-equivalent group.Conclusion. The fixed-dose combination of amlodipine, lisinopril and rosuvastatin, is more effective and equally safe relative to the free-equivalent combination of amlodipine/losartan and rosuvastatin, not only in terms of effect on LDL-C and AI, but also on vascular age parameters calculated using the ASCORE scale. This can serve as an additional motivating factor for patients to receive therapy. |
Author | Batluk, T. I. Latyntseva, L. D. Tsygankova, O. V. |
Author_xml | – sequence: 1 givenname: O. V. orcidid: 0000-0003-0207-7063 surname: Tsygankova fullname: Tsygankova, O. V. organization: Novosibirsk State Medical University; Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences – sequence: 2 givenname: T. I. orcidid: 0000-0002-0210-2321 surname: Batluk fullname: Batluk, T. I. organization: Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences – sequence: 3 givenname: L. D. orcidid: 0000-0003-1913-5231 surname: Latyntseva fullname: Latyntseva, L. D. organization: Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences |
BookMark | eNo9kc9O3DAQh60KJLbAG3DwC6S1Hf-JjxWi7UpIXNqzNTuZLEZZO7IDYp-hL91kF3HyaPTNZ838vrKLlBMxdifFN2k65b9LY0WjhZONEmqtlP3CNsrKrnFWiQu2-SSu2G2tL0IIZWSrO7Fh_7YJCx0ozTwPfH4mTsNAOMc3SlTrqVkI5pj2_Pk4UZkp1ZgTh9Tz_ljHOMWeDhH4a10ZWPA4jcSH-E590-dKHPNhF9Pi-Bhbf3mDiq8jFA77FUhI03zDLgcYK91-vNfs78-HP_e_m8enX9v7H48NKuVs01mjEDyiFbgsaDSgQL9rFRqSBNbswFnpvBcOLFj03qBygAvTabTQXrPt2dtneAlTiQcox5AhhlMjl32AMkccKWjfoVPY4k56TU6DoUFatCRMq2mwi0ufXVhyrYWGT58U4ZRPWK8f1uuHNZ-w5tP-B2Pvh20 |
Cites_doi | 10.1038/nrdp.2018.14 10.1161/CIRCULATIONAHA.105.505636 10.1038/jhh.2013.3 10.1016/j.ijcard.2015.12.015 10.26442/00403660.2019.04.000104 10.1161/JAHA.118.010376 10.1093/eurheartj/ehy339 10.1016/j.ijcard.2017.11.075 10.26442/2075082X.2019.1.190179 10.15829/1560-4071-2018-5-74-80 10.1016/S0140-6736(15)00128-2 10.17116/profmed201619115-23 10.18087/cardio.2019.2.10229 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.15829/1560-4071-2020-4026 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2618-7620 |
ExternalDocumentID | oai_doaj_org_article_498c72c3cb194e74a5ef16c6e0534ef6 10_15829_1560_4071_2020_4026 |
GroupedDBID | 123 642 AAYXX ABDBF ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ VCL VIT |
ID | FETCH-LOGICAL-c2276-8652ca9cc60c76254ac0c9b32c5e1ea65ba76179907a6a6c995c27acc9b84c6a3 |
IEDL.DBID | DOA |
ISSN | 1560-4071 |
IngestDate | Thu Jul 04 21:00:23 EDT 2024 Fri Aug 23 01:36:28 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2276-8652ca9cc60c76254ac0c9b32c5e1ea65ba76179907a6a6c995c27acc9b84c6a3 |
ORCID | 0000-0003-1913-5231 0000-0003-0207-7063 0000-0002-0210-2321 |
OpenAccessLink | https://doaj.org/article/498c72c3cb194e74a5ef16c6e0534ef6 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_498c72c3cb194e74a5ef16c6e0534ef6 crossref_primary_10_15829_1560_4071_2020_4026 |
PublicationCentury | 2000 |
PublicationDate | 2020-09-21 |
PublicationDateYYYYMMDD | 2020-09-21 |
PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-21 day: 21 |
PublicationDecade | 2020 |
PublicationTitle | Rossiĭskiĭ kardiologicheskiĭ zhurnal |
PublicationYear | 2020 |
Publisher | FIRMA «SILICEA» LLC |
Publisher_xml | – name: FIRMA «SILICEA» LLC |
References | ref13 ref12 ref15 ref14 ref20 ref11 ref10 ref21 ref2 ref1 ref17 ref16 ref19 ref18 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref4 doi: 10.1038/nrdp.2018.14 – ident: ref5 – ident: ref7 – ident: ref11 doi: 10.1161/CIRCULATIONAHA.105.505636 – ident: ref16 doi: 10.1038/jhh.2013.3 – ident: ref14 doi: 10.1016/j.ijcard.2015.12.015 – ident: ref20 doi: 10.26442/00403660.2019.04.000104 – ident: ref12 doi: 10.1161/JAHA.118.010376 – ident: ref2 doi: 10.1093/eurheartj/ehy339 – ident: ref13 doi: 10.1016/j.ijcard.2017.11.075 – ident: ref3 doi: 10.26442/2075082X.2019.1.190179 – ident: ref6 doi: 10.15829/1560-4071-2018-5-74-80 – ident: ref9 – ident: ref19 – ident: ref18 – ident: ref1 doi: 10.1016/S0140-6736(15)00128-2 – ident: ref8 doi: 10.17116/profmed201619115-23 – ident: ref10 – ident: ref17 – ident: ref15 – ident: ref21 doi: 10.18087/cardio.2019.2.10229 |
SSID | ssj0002513480 |
Score | 2.185801 |
Snippet | Aim. To study the efficacy, safety and effect on vascular age of free-equivalent and fixed-dose combinations of amlodipine, a renin-angiotensin-aldosterone... |
SourceID | doaj crossref |
SourceType | Open Website Aggregation Database |
StartPage | 4026 |
SubjectTerms | cardiovascular risk dyslipidemia hypertension vascular age |
Title | Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept |
URI | https://doaj.org/article/498c72c3cb194e74a5ef16c6e0534ef6 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07SwQxEA5iITbiE9-ksA3e5bkpVZRDOCsP7JbZSVZt9uRU0N_gn3Ymu8p1NnZLmH3w5dt5JJMZIc5sm6oYGqN0MqBstlFVEFvliT_ggs0-8XrH9M5PZvb2wT0stfrinLC-PHAP3LmNFQaNBhsKt3Ow4HI79ui5pYHNbV9se-yWginWwWS1jS1t0_iksOKoZTg35yodz38HiSSar7i2wpJdWirfX-zMzabYGBxEedF_2JZYWbxvi7XpsAW-I77oj-7X9OS8leS-yT4lY9BaZbA4gt2jfKIgc1FS1OedhC7J9EluZd8TFiSnvD9KIHFebJft80dOKs1fsyQWUsBc5qzcxm_5SVmVpIBIoBx23BWzm-v7q4kaOioo1Dp4VXmnESKiHyFpQWcBRxgbo9HlcQbvGgiea8SNAnjwGKNDHQBJprLoweyJ1W7e5X0hG28Skv2zieYhtE1lAGxI4LDNBo05EOoHz_qlL5xRc8DB-NeMf83414x_zfgfiEsG_VeWy16XASJDPZCh_osMh__xkCOxXljBW0_jY7H6tnjPJ-R5vDWnhWTf-SfU5Q |
link.rule.ids | 315,786,790,870,2115,27957,27958 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increment+of+the+effectiveness+of+treating+hypertension+and+dyslipidemia+using+a+triple+fixed-dose+combination+and+the+vascular+age+concept&rft.jtitle=Rossi%C4%ADski%C4%AD+kardiologicheski%C4%AD+zhurnal&rft.au=O.+V.+Tsygankova&rft.au=T.+I.+Batluk&rft.au=L.+D.+Latyntseva&rft.date=2020-09-21&rft.pub=FIRMA+%C2%ABSILICEA%C2%BB+LLC&rft.issn=1560-4071&rft.eissn=2618-7620&rft.volume=25&rft.issue=9&rft_id=info:doi/10.15829%2F1560-4071-2020-4026&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_498c72c3cb194e74a5ef16c6e0534ef6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1560-4071&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1560-4071&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1560-4071&client=summon |